SynthesisBMJ open2023
Prognostic significance of platelet-to-lymphocyte ratio (PLR) in patients with breast cancer treated with neoadjuvant chemotherapy: a meta-analysis.
Synthesis in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prognostic value of the HALP score in breast cancer: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- Prognostic value of platelet to lymphocyte ratio (PLR) in breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Remnant cholesterol inflammatory index for predicting pathological complete response to neoadjuvant therapy in breast cancer: A multicenter external validation study.Breast (Edinburgh, Scotland) · 2026Article
- Dynamic nomogram for predicting axillary lymph node metastasis in breast cancer based on MRI analysis and the platelet-to-lymphocyte ratio (PLR).Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Salivary Metabolic Characteristics and Response to Neoadjuvant Systemic Therapy in Breast Cancer.International journal of molecular sciences · 2026Article
- Investigating the predictive role of inflammatory indices in cancer metastasis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- The association between systemic inflammation markers and breast cancer.Scientific reports · 2026Article
- Article
- Ultrasonographic features and inflammatory status associated with tumor size in breast invasive ductal carcinoma.American journal of translational research · 2026Article
- Correlation of quantitative background parenchymal enhancement with prognostic factors in breast cancer.Frontiers in oncology · 2026Article
- A Prognostic Nutritional Scoring System Integrating Inflammatory Markers and Body Composition in Gastric Cancer Patients Undergoing Curative Resection With Prophylactic HIPEC.Gastroenterology research and practice · 2026Article
- Comparative associations of immune-inflammatory, immune-lipid, and metabolic composite indices with hyperuricemia among Chinese adults with glycemic abnormalities: a health examination-based cross-sectional study.Frontiers in endocrinology · 2026Observational
- Machine learning and SHAP value interpretation for predicting the response to neoadjuvant chemotherapy and long-term clinical outcomes in Chinese female breast cancer.Annals of medicine · 2025Article
- Immune and Inflammation Markers as a Predictor of Overall Survival in Patients with Hematologic Malignancies: A Retrospective Cohort Study.Medicina (Kaunas, Lithuania) · 2025Article
- Prognostic value of combined NP and LHb index with absolute monocyte count in colorectal cancer patients.Scientific reports · 2025Article
- Platelet-to-lymphocyte ratio as a prognostic biomarker in patients with human epidermal growth factor receptor 2-negative breast cancer undergoing taxane-carboplatin-based neoadjuvant chemotherapy.Therapeutic advances in medical oncology · 2025Article
- Predictive model using systemic inflammation markers to assess neoadjuvant chemotherapy efficacy in breast cancer.Frontiers in oncology · 2025Article
- Prognostic utility of inflammatory indices and circulating nucleic acids for neoadjuvant chemotherapy outcomes in breast cancer: a systematic review.Therapeutic advances in medical oncology · 2025Review
- Development and validation of a Comprehensive Hematological Scoring System for predicting overall survival in patients with soft tissue sarcomas: a comparison with NLR and PLR.Frontiers in oncology · 2025Article
- Evaluating the Role of CBC-Derived Indices in Children with Hashimoto's Thyroiditis.Diagnostics (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePlatelet-to-lymphocyte ratio (PLR), known as a key systemic inflammatory parameter, has been proved to be associated with response to neoadjuvant therapy in breast cancer (BC); however, the results remain controversial. This meta-analysis was carried out to evaluate the prognostic values of PLR in patients with BC treated with neoadjuvant chemotherapy (NACT).
designMeta-analysis. DATA SOURCES: Relevant literature published on the following databases: PubMed, Embase, Web of Science databases and the Cochrane Library. ELIGIBILITY CRITERIA: All studies involving patients with BC treated with NACT and peripheral blood pretreatment PLR recorded were included. DATA EXTRACTION AND SYNTHESIS: Two researchers independently extracted and evaluated HR/OR and its 95% CI of survival outcomes, pathological complete response (pCR) rate and clinicopathological parameters.
resultsThe last search was updated to 31 December 2022. A total of 22 studies with 5533 patients with BC treated with NACT were enrolled in the final meta-analysis. Our results demonstrate that elevated PLR value appears to correlate with low pCR rate (HR 0.77, 95% CI 0.67 to 0.88, p<0.001, I
conclusionsThis meta-analysis demonstrated that high PLR was significantly related to the low pCR rate, poor OS and disease-free survival (DFS) of patients with BC treated with NACT. Therefore, PLR can be used as a potential predictor biomarker for the efficacy of NACT in BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.